Table 3 Baseline characteristics of patients of the two studied cohorts.
A - Multiple sclerosis | Overall (n = 629) | First line treatment | Relapse at 1 year | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Ntz (n = 326) | Fng (n = 303) | p | No (n = 478) | Yes (n = 151) | p | |||||||
Patient age, years (mean, sd) | 37.0 | 9.6 | 36.8 | 9.9 | 37.2 | 9.2 | 0.6505 | 37.1 | 9.7 | 36.6 | 9.2 | 0.5849 |
Female patient (n, %) | 479.0 | 76.2 | 254.0 | 77.9 | 225.0 | 74.3 | 0.2822 | 367.0 | 76.8 | 112.0 | 74.2 | 0.5124 |
Disease duration, years (mean, sd) | 8.5 | 6.4 | 8.0 | 6.1 | 9.0 | 6.8 | 0.0505 | 8.6 | 6.6 | 8.2 | 6.0 | 0.4809 |
At least one relapse (n, %) | 526.0 | 83.6 | 293.0 | 89.9 | 233.0 | 76.9 | <0.0001 | 391.0 | 81.8 | 135.0 | 89.4 | 0.0277 |
Gd-enhancing lesion on MRI (n, %) | 311.0 | 49.4 | 185.0 | 56.7 | 126.0 | 41.6 | 0.0001 | 240.0 | 50.2 | 71.0 | 47.0 | 0.4944 |
EDSS score >3 (n, %) | 288.0 | 45.8 | 166.0 | 50.9 | 122.0 | 40.3 | 0.0074 | 212.0 | 44.4 | 76.0 | 50.3 | 0.1986 |
Previous immunomodulatory treatment (n, %) | 556.0 | 88.4 | 293.0 | 89.9 | 263.0 | 86.8 | 0.2284 | 424.0 | 88.7 | 132.0 | 87.4 | 0.6672 |
B – ICU | Overall (n = 252) | Barbiturates treatment | Favourable GOS at 3 months | |||||||||
No (n = 178) | Yes (n = 74) | p | No (n = 180) | Yes (n = 72) | p | |||||||
Patient age, years (mean, sd) | 47.4 | 17.4 | 48.7 | 17.9 | 44.1 | 15.7 | 0.0565 | 50.8 | 16.4 | 38.7 | 16.9 | <0.0001 |
Female patient (n, %) | 89.0 | 35.3 | 58.0 | 32.6 | 31.0 | 41.9 | 0.1592 | 68.0 | 37.8 | 21.0 | 29.2 | 0.1963 |
Diabetes (n, %) | 17.0 | 6.7 | 15.0 | 8.4 | 2.0 | 2.7 | 0.0989 | 15.0 | 8.3 | 2.0 | 2.8 | 0.1122 |
Nosological entity: Severe trauma (n, %) | 124.0 | 49.2 | 95.0 | 53.4 | 29.0 | 39.2 | 0.0403 | 77.0 | 42.8 | 47.0 | 65.3 | 0.0012 |
SAP ≤90 mmHg before admission (n, %) | 56.0 | 22.2 | 36.0 | 20.2 | 20.0 | 27.0 | 0.2368 | 46.0 | 25.6 | 10.0 | 13.9 | 0.0442 |
Evacuation of subdural or extradural hematoma (n, %) | 41.0 | 16.3 | 33.0 | 18.5 | 8.0 | 10.8 | 0.1301 | 27.0 | 15.0 | 14.0 | 19.4 | 0.3878 |
External ventricular drain (n, %) | 64.0 | 25.4 | 39.0 | 21.9 | 25.0 | 33.8 | 0.0486 | 48.0 | 26.7 | 16.0 | 22.2 | 0.4640 |
Evacuation of cerebral hematoma or lobectomy (n, %) | 42.0 | 16.7 | 28.0 | 15.7 | 14.0 | 18.9 | 0.5362 | 34.0 | 18.9 | 8.0 | 11.1 | 0.1345 |
Decompressive craniectomy (n, %) | 27.0 | 10.7 | 15.0 | 8.4 | 12.0 | 16.2 | 0.0686 | 21.0 | 11.7 | 6.0 | 8.3 | 0.4396 |
Blood transfusion before admission (n, %) | 34.0 | 13.5 | 25.0 | 14.0 | 9.0 | 12.2 | 0.6903 | 26.0 | 14.4 | 8.0 | 11.1 | 0.4841 |
Pneumonia before increased ICP (n, %) | 29.0 | 11.5 | 16.0 | 9.0 | 13.0 | 17.6 | 0.0519 | 19.0 | 10.6 | 10.0 | 13.9 | 0.4538 |
Osmotherapy (n, %) | 112.0 | 44.4 | 75.0 | 42.1 | 37.0 | 50.0 | 0.2525 | 89.0 | 49.4 | 23.0 | 31.9 | 0.0115 |
GCS score ≥8 | 62.0 | 24.6 | 39.0 | 21.9 | 23.0 | 31.1 | 0.1237 | 37.0 | 20.6 | 25.0 | 34.7 | 0.0183 |
Hemoglobin, g/dL (mean, sd) | 11.8 | 2.3 | 11.7 | 2.2 | 12.1 | 2.5 | 0.1824 | 11.8 | 2.4 | 11.9 | 1.9 | 0.7373 |
Platelets, counts/mm3 (mean, sd) | 206.7 | 78.0 | 207.4 | 79.7 | 205.1 | 74.2 | 0.8312 | 209.0 | 83.8 | 200.9 | 61.1 | 0.4589 |
Serum creatinine, mmol/L (mean, sd) | 71.1 | 29.3 | 71.1 | 27.6 | 71.1 | 33.3 | 0.9853 | 72.4 | 32.6 | 67.9 | 18.7 | 0.2732 |
Arterial pH (mean, sd) | 7.3 | 0.1 | 7.3 | 0.1 | 7.3 | 0.1 | 0.0978 | 7.3 | 0.1 | 7.3 | 0.1 | 0.6317 |
Serum proteins, g/L (mean, sd) | 58.2 | 10.4 | 57.7 | 10.6 | 59.6 | 9.7 | 0.1662 | 58.0 | 10.7 | 58.8 | 9.7 | 0.5963 |
Serum urea, mmol/L (mean, sd) | 5.0 | 2.5 | 5.2 | 2.7 | 4.7 | 1.8 | 0.1827 | 5.2 | 2.3 | 4.5 | 2.9 | 0.0505 |
PaO2/FiO2 ratio (mean, sd) | 302.7 | 174.0 | 292.7 | 154.7 | 326.6 | 212.9 | 0.1595 | 282.1 | 172.4 | 354.2 | 168.4 | 0.0028 |
SAPS II score (mean, sd) | 47.6 | 11.4 | 47.6 | 10.7 | 47.6 | 12.9 | 0.9847 | 49.9 | 10.8 | 41.8 | 10.7 | <0.0001 |
